Palatin Technologies, Inc. to Sponsor “Role of Novel Mechanisms in the Treatment of Sexual Dysfunction and and Palatin’s PT-141 Drug Candidate”
CRANBURY, NJ –January 7, 2004 –Palatin Technologies, Inc. (AMEX: PTN) announced today that it will sponsor a presentation on the “Role of Novel Mechanisms in the Treatment of Sexual Dysfunction and Palatin’s PT-141 Drug Candidate”, taking place on January 8, 2004 in New York City. The presentation will begin at 12:00 noon EST and individuals who are not registered to attend can access the presentation via Teleconference/Webcast.
Carl Spana, Ph.D., President and Chief Executive Officer of Palatin, will be moderating the forum which will include presentations on the scientific rationale for centrally-acting agents in the treatment of sexual dysfunction, clinical experience and future clinical development plans for PT-141, Palatin’s lead drug candidate under development for male and female sexual dysfunction, and an assessment of the sexual dysfunction market and competitive positioning of Palatin’s PT-141. The presentation will include an overview of Palatin’s recently released positive Phase 2B “at home” study results which demonstrated that men with erectile dysfunction taking the intranasally administered drug PT-141 reported consistently improved erectile function across all dosing levels.
The following individuals will present at this meeting:
- François Giuliano, M.D., Ph.D., who is a Urologist associated with the Medical University of Paris South and head of the Male Sexual Dysfunction Program at the Academic Hospital of Bicêtre in France, will present the scientific rationale for centrally-acting agents in the treatment of sexual dysfunction. Dr. Giuliano is internationally recognized for his expertise in the experimental approach to the neurophysiology of penile erection and serves on the executive committee of the European Society for Impotence Research.
- Harin Padma-Nathan, M.D., FACS, FRCS(C), Clinical Professor of Urology at the University of Southern California and director of the Male Clinic in Beverly Hills, will provide an overview of the clinical experience and positive results obtained from Palatin’s Phase 2B “at home” study of PT-141 for male sexual dysfunction. Dr. Padma-Nathan’s research and clinical practice are focused on pharmacotherapy for sexual dysfunction.
- Perry Molinoff, M.D., Chairman of Palatin’s Clinical Advisory Board and Vice Provost for Research and A.N. Richards Professor of Pharmacology, Emeritus at the University of Pennsylvania, will present Palatin’s future clinical development program for PT-141. Marc Kozin, President, of L.E.K. Consulting, will present an assessment of the sexual dysfunction market and the competitive positioning of PT-141.
Teleconference & Webcast Access Information
Thursday, January 8, 2004, 12:00-2:30 PM EST
Listen via Internet:
§ To listen to the live presentation, please go to the Web at least 15 minutes prior to the start of the call to register and download and install any necessary audio software.
§ To listen to the presentation over the Internet, access the webcast link at the company website, www.palatin.com.
§ A replay of the webcast will be available on the company’s website, www.palatin.com, beginning 4:30 PM EST on January 8, 2004 and will be available until 12:00 PM EST on January 15, 2004.
Listen to Live Presentation via Telephone:§ To listen by phone, please call ten minutes prior to the presentation start time (12:00 PM EST):
U.S. Callers: 1-800-915-4836
International Callers: 1-973-317-5319
§ Advise the Operator that you are calling for the Palatin Technologies Teleconference
Replay of Presentation by Phone:§ A replay of the presentation will be available beginning 4:30 PM EST on January 8, 2004 through 12:00 PM on January 15, 2004.
§ To access the replay by phone:
U.S. Callers: 1-800-428-6051
International Callers: 1-973-709-2089
Enter the pass code ID # 326369
About PT-141
PT-141 is the first of a new class of drugs called melanocortin agonists being developed to treat sexual dysfunction. The mechanism of action of PT-141 may offer significant safety and efficacy benefits over currently available products because it acts on the pathway that controls sexual function without acting directly on the vascular system. Clinical data indicates that PT-141 may be effective in treating a broad range of patients suffering from ED. The nasal formulation of PT-141 being developed is as convenient as oral treatments, is more patient-friendly than invasive treatments for ED, such as injections and trans-urethral pellets, and appears to result in a rapid onset of action.
About Erectile Dysfunction (ED)
ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. (AMEX: PTN) is a biopharmaceutical company focused on discovering and developing melanocortin-based (MCR) therapeutics. The company is currently conducting clinical investigations with its lead drug PT-141, a MCR agonist, for the treatment of male and female sexual dysfunction. Palatin is also developing a product for infection imaging, LeuTechâ, based on a proprietary radiolabeled monoclonal antibody. Palatin’s patented drug discovery platform, MIDASTM, streamlines the drug design process with an efficient approach to identify lead compounds from protein targets for drugs. For further information, visit the Palatin web site at www.palatin.com.
Statements about the Company's future expectations, including development and regulatory plans, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from its historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of technology, the risk that products may not result from development activities, protection of its intellectual property, ability to establish and successfully complete clinical trials for product approval, need for regulatory approvals, dependence on its partners for development of certain projects, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for events not updated after the date on this press release.
- End -
HOME
PT-141
Nasal spray
"Bliss in a Pill"?
Sensualism.com
Sexual Healing(?)
New sex drug study
Palatin Technologies
Designer Aphrodisiacs
PT-141 Arouses Women
Melanton Discussion Board
PT141 : "Bigger Than Viagra"
PT-141 : the first aphrodisiac
The 21st Century Aphrodisiac?
Palatin Technologies Raise Capital
Reverse engineering the female orgasm
PT-141 / bremelanotide Fact Sheet (PDF)
PT-141 (bremelanotide): the female Viagra?
Lust drug and slimming pill : PT-141 ("Passion")
info@bremelanotide.co
